


-- SP64 E1A E1Apr 0 10 20
pNeuEcoRI-CAT E1A(μ g)

FIG. 1A




RSV SP64 E1A E1B E2A E3
pNeuEcoRI-CAT

FIG. 1B




0 20 15 10 5
EIA (μ g)

FIG. 2A




0 20 15 10 5
EIA-13S(μ g)

FIG. 2B




0 20 15 10 5
EIA-12S (μ g)

FIG. 2C



0 20 15 10 5
EIA d1346 (μ g)

FIG. 2D





Repression
of *neu*
+

+

-

-

FIG. 2E

FIG. 3AFIG. 3B




FIG. 4A





FIG. 4B

<u>E1A(μg)</u>	-	10	10	10
<u>Oligo n.t.</u>	-	Cons	Nonc	-



Relative CAT(100%): 100 89 36 29

5'-TCTTGCTIGGAATGCAGTTGG-3'

FIG. 5





FIG. 6AFIG. 6BFIG. 6CFIG. 6D



FIG. 7A




FIG. 7D



FIG. 7B




FIG. 7E






FIG. 7C




FIG. 7F

104E80-156E1560

**FIG. 8A****Soft Agar Colony Formation Assay****FIG. 8B**

Tumorigenicity assay

Cell Line	Time to develop tumors (No. of tumors/no. of injection)					Tumor volume at 16 days (mm ³)
	8	12	14	20	26 (days)	
B104-1-1	6/6	6/6	6/6	6/6	6/6	8240±203
NIH3T3	0/6	0/6	0/6	0/6	0/6	N.D.
N-E1A-1	0/6	0/6	0/6	0/6	0/6	N.D.
B-E1A-1	0/6	0/6	0/6	5/6	6/6	N.D.
B-E1A-2	0/6	2/6	6/6	6/6	6/6	216±53
B-E1A-3	0/6	6/6	6/6	6/6	6/6	481±74



FIG. 9A



NIH3T3

B-E1A-2

B104-1-1

FIG. 9B

FIG. 10AFIG. 10B






FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 19

NIH3T3 BTn14



FIG. 20A




FIG. 20B




FIG. 20C




FIG. 21



(1)

(2)

(3)

FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26B



60624660-1660-60624660

FIG. 27




FIG. 28A




FIG. 28B




FIG. 28C




FIG. 29A




FIG. 29B



FIG. 29C




FIG. 30A




FIG. 30B




FIG. 31A




FIG. 31B




FIG. 32A




FIG. 32B




FIG. 33C

Low Infection Protocol





FIG. 33D



High Infection Protocol

FIG. 33A

MDA-MB-453






FIG. 33B

MDA-MB-435



High Infection Protocol

FIG. 34A



Low Infection Protocol

FIG. 34C




FIG. 34B




FIG. 35




FIG. 36A




FIG. 36B

